Mapping the Terrain

Mapping the Terrain Thailand’s first National Biotechnology Policy Framework served as a roadmap for significant progress, but it had a rocky start. A look back at the Framework provides signposts to guide the way forward. During the past 3 decades, Thailand has increasingly prioritized biotechnology investment. From medicine to food to plastics to energy, Thailand has emerged as a key player in biotechnology research and development in Asia. Well before many countries paid any attention to the role biotechnology would play in their institutions, economies, and lifestyles, Thailand realized the importance of getting organized or being left behind. Today’s Thailand has a vast pool of trained researchers and technicians with wage rates among the most competitive in the world, a rich reservoir of untapped biodiversity resources, a legal framework supportive of creative research, and among the most generous biotechnology investment incentives of any country in the world. Thailand’s biotechnology strategy aims to make the country a global leader, but it does so with a philosophy that is inherently Thai, says Sakarindr Bhumiratana, president of Thailand’s National Science and Technology Development Agency (NSTDA). “Where possible, we emphasize research that will improve the livelihood and quality of life of our citizens across the board. That is why we’ve become a key player in infectious disease research, agricultural biotechnology to help farmers, and alternative energy from abundant biomass,” says Sakarindr. “We really do want to see the whole society benefit as we grow this segment of our economy.” THE EARLY DAYS When United Nations consultants traveled to Bangkok in the early 1980s searching for a location for the International Center for Genetic Engineering and Biotechnology, the country’s scientific community was abuzz. Thailand’s status as a high-tech research hub was validated when the country was shortlisted for the new facility. But once the search committee chose India, principally because Thailand lacked a dedicated national biotechnology agency, the euphoria turned to despair. “That was the clinching moment,” recalls Yongyuth Yuthavong, NSTDA’s senior advisor. “Top policy makers and chief scientists decided right there and then that Thailand must have its own National Center for Genetic Engineering and Biotechnology.” When it opened in 1983, the National Center for Genetic Engineering and Biotechnology (BIOTEC) already had at its disposal established scientific institutions and researchers active in the basic life sciences, medicine, and agriculture. In fact, the roots of the pioneering thalassemia research Thailand is engaged in now go back to groundbreaking work begun 2 decades before BIOTEC’s conception. In 1964, Prawase Wasi discovered the genetic mechanism of hemoglobin H disease, proving that it is related to α-thalassemia. His work was published in the British scientific journal Nature, and two genes are now known as Wasi’s α-thalassemia-1 and Wasi α-thalassemia-2. The Next Generation When Jariya Sakayaroj first peered into a microscope during a biology class, she had no idea she was looking at her future. The thought of a girl from her rural village becoming a serious scientist was too farfetched for her to imagine. But 20 years later, as one of BIOTEC’s principle microbiologists, Jariya is leading efforts to unravel the secrets of local microorganisms for pharmaceutical applications in collaboration with Novartis. Thailand’s research institutes are full of stories like Jariya’s, the result of an expanding network of programs across the country that are designed to nurture the brightest scientific minds to increase the talent pool for the life-sciences industry. Starting in 1990, the Royal Thai Government set up a Thai Government Science and Technology Scholarship Program, with an objective to generate a critical mass of scientists and academics in 6 major fields—biotechnology, material science, computer science, nanotechnology, basic science, and technology management—to supply to universities, research institutes, and government agencies, including NSTDA. Talented high-school students were recruited from all over the country to receive overseas university education, all the way to PhD, mainly in North America, Europe, Japan, and Australia. More than 3,000 scholarships were granted through 2009. So far, the program has produced over 100 PhD graduates in biotech-related fields. “Grooming young talent to become scientists is the best way to secure Thailand’s positioning in the era of science-based economies,” says Morakot Tanticharoen, vice president of the National Science and Technology Development Agency (NSTDA). “The country’s demand for scientists is growing in both government research institutes and within private-sector R&D.” Jariya is among more than 1,000 participants to enroll in the NSTDA-initiated Thailand Graduate Institute of Science and Technology program since it began in 1998. Overall, NTSDA awards 3,000 scholarships annually for students pursuing science degrees, many of whom come from the country’s special science-focused high schools. For younger scholars, NTSDA operates Sirindhorn Science House at its Thailand Science Park campus, where students from across the country participate in short-term immersion programs with working scientists. The facility includes a laboratory and a live-in center for 200 participants. In addition, BIOTEC has initiated the Human Resource Development Program in Biotechnology for Neighboring Countries. The program, which is funded by The Association of Southeast Asian Nations (ASEAN) and the New Zealand UNESCO Commission, has trained a steady stream of researchers from ASEAN countries and provides a networking platform for ASEAN researchers.—Weena Yoswangjai By the early 1980s, Thai scientists had already mastered the basics of plant-cell culture technique and clonal propagation, which they applied to improving orchids and other cut flowers. Rapee Sagrik’s work on the art of hybridization in orchids helped launch Thailand’s orchid export industry, which now generates $60 million annually. Rapee’s creative use of natural and human resources exemplified BIOTEC’s mandate to further Thailand’s economic and social development through the application of science. In its first decade, BIOTEC focused on establishing networks of experts to facilitate collaboration, while also supporting the development of laboratories at academic institutions. In the 1990s, relevant policy and regulatory frameworks were strengthened, and increased attention was paid to intellectual property management, biosafety guidelines, and public education and outreach. While BIOTEC was getting organized during its first 2 decades, a lot of valuable research was already under way, says Yongyuth, notably the development of new crop varieties with resistance to a wide array of biotic and abiotic stresses, medical research into tropical diseases, and studies of new ways to turn biomass and agricultural byproducts into biofuels. A VISION FOR BIOTECHNOLOGY Leading figures in Thai biotechnology convened intermittently over 6 months in 2003 to develop the country’s first National Biotechnology Policy Framework. Spanning the years 2004–2009, the Framework included goals in six main categories: business development, agriculture, medicine, renewable energy, self-sufficient economy, and human resources. A retrospective shows that in the 5 years covered by the Framework, the country made significant strides, although there is clearly work left to be done. Business Development Thailand hoped to see the emergence of no less than 100 new biotechnology companies established by 2010, but it came up a bit short. Ninety new companies were established during the period covered by the Framework, bringing the country’s total to approximately 170. Many companies have taken advantage of the incentives BIOTEC has arranged through Thailand’s Board of Investment (BoI), including an 8-year exemption on corporate income tax, exemptions on machinery import duties, and deductions for energy, transportation, and facility construction fees. “Biotechnology is classified as priority activity, which has special importance and benefits to the country,” says Ajarin Pattanapanchai, BoI’s deputy secretary general, adding that the agency pays special attention to investment in R&D in the areas of the seed industry; plant and animal improvement; biopharmaceutical agents; diagnostic kits for health, agriculture, food, and the environment; and bimolecular and bioactive compounds using microorganisms, plant cells, and animal cells. Debate remains about whether the government has done enough for the business of biotech, but clear progress has been made. “The efforts of Thailand to foster the scientific education during the last 2 decades resulted in a new generation of young and highly talented scientists with a broad experience in natural products research and beyond,” says Frank Petersen, executive director, Natural Products Unit, Novartis Institutes for Biomedical Research. “Such a decisive governmental objective is an ideal situation for an industry partner to initiate sustainable capacity building in a respective country.” NSTDA’s Sakarindr had hoped his agency’s recruiting efforts would encourage more of the industry’s multinational players to consider Thailand as the base for their regional activities, but he says the country’s unsettled political climate, with one coup and three changes in government since the Framework was launched, has often been a deterrent. “Once the (political) situation improves, things could take a turn for the better in no time,” he says. “One thing we’ve got in the pipeline is utilizing the procurement process to provide additional incentives for large international suppliers that are also willing to invest in biotechnology R&D here.” Additional benefits are available to companies that set up operations at NSTDA’s Thailand Science Park, a high-tech campus that opened in 2002 and houses BIOTEC, three other technology agencies, and more than 60 private companies. A 120,000-square-meter second phase will be opening next year and is expected to house 200 companies. © Frank van den Bergh Agriculture Employing 40 percent of the country’s workforce and generating $20 billion in export earnings, agriculture is a major target for biotechnology resources in Thailand. Under the banner “Kitchen of the World,” the Framework outlined strategies to improve output from the country’s core crops as well as to stimulate increased investment in the production and export of value-added products like mineral-enriched rice and processed fruits. A visit to any one of the specialized rice, shrimp, cassava, or sugar research stations dotting the country would reveal that scientists have been productive fulfilling the first aim. Using gene pyramiding, researchers have created new rice varieties that are more disease resistant and flood and drought tolerant, and those products are making their way to the fields. Through nucleus breeding, efforts are now under way to keep Thailand a leader in shrimp exports by developing the world’s highest-quality black tiger shrimp. Some researchers are developing new sugar cane and cassava varieties, while others are finding ways to more efficiently extract energy from the byproducts generated when these crops are processed for their sugar and starch. One concern, says Morakot Tanticharoen, vice president of NSTDA, is that restrictions on field testing, cultivation, and export of genetically modified organisms have been limiting Thai scientists’ progress. “Other major agricultural producers have been working with GMO crops for years,” says Morakot. “Thailand needs to join them. The door may be open for case-by-case GMO field trials, but the Biosafety Bill needs to get out of Parliament.” Thailand Science Park Not long after Thailand Science Park (TSP) opened for business in 2002, one of its tenants began making international headlines for a biotechnology breakthrough. From their labs at TSP, researchers at BIOTEC spent days answering phone calls and emails about their groundbreaking work on an immunochromotagraphic strip test for alpha-thalassemia-1. While the roots of that achievement were in more antiquated facilities elsewhere, the discovery drew attention to the ultramodern, 32-hectare TSP campus and the research quality and intellectual rigor that can be found there. TSP, which is run by Thailand’s National Science and Technology Development Agency (NSTDA), is also home to the National Metal and Materials Technology Center, National Electronics and Computer Technology Center, and National Nanotechnology Center. Three of Thailand’s leading universities are nearby, contributing to a creative synergy that has attracted 62 private tenants to TSP, 30 of which are headquartered in other countries. “The atmosphere here is excellent. Everyone talks about science, which continuously motivates our R&D team,” says Vanus Taepaisitphongse, CEO of Betragro, one of Thailand’s leading agribusiness groups. Pramote Techasupatkul, President of Siam Cement Group, is also enthusiastic about the scientific climate at TSP. “The establishment of our Green Nanomaterials Research Center at Thailand Science Park reflects our research and development mission and offers SCG researchers [the chance] to work among Thailand’s leading scientists,” he says. A core objective for TSP management is to offer both lab-to-market and market-to-lab services to tenants, according to Chatchanat Thebtaranonth, Director of TSP’s Technology Management Center. “If companies have problems introducing their products to the market, we help them get these problems solved,” she stresses. The fully-integrated R&D hub has proved so popular that NSTDA has broken ground on an additional 120,000m2 complex scheduled to be completed next year. When the new doors open, much of that space is expected to be occupied, given the special tax breaks and other incentives offered to companies that occupy the Park. It will be interesting to see which one of them makes headlines first. —Weena Yoswangjai New value-added products from Thai agriculture were initially slow to develop under the Framework, but recent developments in the area of bioplastics ramped things up. The 2008–2012 bioplastics road map has stimulated research on sugarcane, cassava, and corn. “With global plastic production at 250 million tons a year, less than a million tons now come from biosources. There is a lot of room for bioplastics to grow to penetrate this market,” says Wantanee Chongkum, director of the Innovation Management Department at the National Innovation Agency. “As the world’s eighth-largest plastics manufacturer, with high agricultural productivity, we’re well positioned to fuse these two ingredients to become the center of the world’s bioplastics production.” Medicine Over the past decade, Thailand has become a leader in research on diseases that plague developing countries such as malaria, dengue fever, tuberculosis, HIV, and thalassemia. “It does seem to be a niche market that we now occupy,” says Komkrit Sajjaanantakul, managing director of I+MED Laboratories. “Increasingly, however, tropical diseases are being found in northern latitudes, so we may find huge markets overseas in the years to come.” A major growth area under the Framework has been the development and production of diagnostic test kits, principally for the domestic market, fueled largely by government R&D and financial support. Thailand has the manufacturing competitiveness to grow this industry overseas, but so far there’s been little effort toward developing a medical device certification process that would give confidence to international buyers, says Komkrit. Thailand has also emerged as a competitive location for large-scale clinical drug trials. Most recently, the world’s largest HIV vaccine clinical trials were conducted in Thailand in 2009. “As the cost for trials continues to escalate, I think we are going to be seeing a lot more companies looking to Thailand as among the most competitive locations to conduct this research,” says Sutee Yoksan, director of Mahidol University’s Center for Vaccine Development. Surrounding all this activity is a medical care infrastructure that is among the best in Southeast Asia, attracting 1.2 million medical tourists in 2009. The National Institute of Development Administration found that the combination of treatment quality, price, and atmosphere attracts more foreign patients to Thailand than to its two regional competitors, India and Singapore. Renewable Energy The past 5 years have seen a huge increase in the number of biogas and ethanol plants across Thailand, which are aimed at getting the most power possible from agricultural products. “Bioenergy has probably been among the most impacted by biotechnology under the Framework,” says energy expert Suvit Tia of King Mongkut’s University of Technology Thonburi. “As a relatively new sector, there’s been a lot more room for science to affect change as compared to something researchers have been experimenting with for generations.” However, care must be taken to ensure that this progress doesn’t come at too high a cost, Suvit maintains. “Like many other countries, the one issue we need to watch out for is that our alternative energy generation does not take food off our table. Assistance for the further expansion of this industry should not come at the expense of higher domestic food prices,” he says. Self-sufficient Economy Thailand’s rich biological diversity is a major attraction for biotechnology companies. The country is home to about 10 percent of the world’s total plant species and microorganisms, and drug makers in particular are keen to explore these resources. While still new to scientists, many of these species are quite familiar to the locals in Thailand’s rural communities, so it’s not surprising that the biotechnology framework paid special attention to sustainable development. © Sura Nualpradid The Framework included biodiversity protection programs to minimize the likelihood that species will disappear. It also focused on opportunities for local residents to partner in the collection and exploration of plants and to share their indigenous knowledge, creating new ways to support rural livelihoods. In addition, the Framework called for the development of organic fertilizers specific to local areas, methods for biogas generation, and the development of new crop and aqua culture varieties to help small farmers maintain competitiveness. Success Stories For international companies seeking to establish a base for biotech R&D or manufacturing in Thailand, the pharma giant Novartis and the East West Seed Company offer success stories that may serve as models. Alexandre F. Jetzer, a member of Novartis’s board of directors, says the company created an R&D partnership with Thailand’s National Center for Genetic Engineering and Biotechnology (BIOTEC) to explore natural substances derived from the country’s rich microbial diversity, which have great potential to be developed into new drugs. “Thailand has a fantastic potential. You have a pool of great scientific talents and a strong knowledge base,” Jetzer says. “I believe in the country’s strong future as an investment destination for R&D.” From 2005 to 2008, Novartis worked to develop the capacity of Thai scientists in two areas: the application of microbiological technologies and concepts, and natural-products research to produce new molecules from novel microorganisms of high diversity for drug discovery. Now in its second 3-year tranche, the partnership is working to expand the acquisition of strains to increase access to the diversity of the microbial substances. The East West Seed Company has been taking advantage of Thailand’s research climate for nearly 3 decades. The company’s vice president of R&D, Simon Jan de Hoop, says Thailand’s central location in Southeast Asia, the size of its domestic market, the availability of good seed-producing farmers, and the country’s business incentives have served his company well. “Thailand has some good agricultural universities and research institutes that we can work with in identifying good people and knowledge exchange,” de Hoop says. But he notes that practical, applied plant breeding is not as well developed as it should be in an agricultural country of Thailand’s size. East West Seed president Joost Pekelharing says Thailand should invest in a university program for plant breeders. “With the current university graduates, the company has to work from scratch to train them to become good breeders, which takes at least 6 to 7 years,” he says. Both Novartis and East West Seed benefit from government incentives that include exemptions for import duty on machinery and tax holidays with no exemption caps on investments in biotech R&D. —Pennapa Hongthong “For example, in areas where there are huge quantities of agricultural waste such as rice, straw, and maize husk, certain enzymes can be used to speed up their decomposition so that they can be used as biofertilizers instead of being disposed of by burning,” says Kanyawim Kirtikara, BIOTEC’s executive director. Human Resources Thailand aims to become a “knowledge-based” economy. The continued growth in the scientific capabilities of its students and workforce is seen as paramount, not only for biotechnology but for technology generally, says Morakot Tanticharoen, vice president of NSTDA. The government is opening new colleges every few years, working closely with foreign scholars in overseas research institutes, and providing more scholarships to science students. With the proliferation of graduate programs at home, fewer students need to attend foreign universities, says Uthaiwan Grudloyma, manager of BIOTEC’s Policy Studies and Biosafety Division. “We are still supporting students going abroad, but they are on the whole pursuing higher-caliber studies and more specialized research.” “Brain drain” is a problem for Thailand, as it is for most developing countries. Many talented scientists take posts overseas, and within Thailand, researchers often migrate out of public laboratories and hospitals to the private sector, where the wages are higher. But an increasingly larger pool of scientists should help counteract the problem, says BIOTEC’s Uthaiwan. In fact, the agency supports its researchers moving to the private sector to strengthen the link between public and private entities, he says. THE ROAD AHEAD Despite the gains made under the Framework, many feel some of its elements were overambitious and detracted from its integrity. For example, agriculture revenues skyrocketed, propelling Thailand from 12th place to fifth among the world’s leading agricultural exporting nations in just 6 years. During the same period, hospitals and medical care in Bangkok became the most sought after in Asia. The Framework also suffered from insufficient dedicated funding. Biotechnology programs relied mostly on the annual budgets of the relevant government agencies to achieve the Framework’s objectives. The supplemental public funds that many agencies and research institutions believed would be forthcoming did not materialize. “Some perfectly good plans become unrealistic because of limited resources available to us,” Sakarindr says. These issues will almost certainly be discussed when the nation’s scientists convene in June to begin planning the next iteration of a national biotechnology strategy. While the work will begin with a clean slate, BIOTEC’s Uthaiwan says some of the priorities will undoubtedly remain the same. “The big sector is agriculture. Food always comes first,” stresses Uthaiwan. “Bioenergy and the environment are also high on the agenda. The direction to go is to make the best use of our rich biodiversity for the well-being of our people and for environmental protection. We will also see a convergence of technologies around biotech for better handling of these key issues of national importance under the new framework.” The process cannot start soon enough, say some scientists. They feel it’s time for the scientific community and policy makers to recognize the gains made under the Framework but to accept that not all of its goals may have been achievable. “Absent the Framework, we would not have come this far,” says Uthaiwan. “We’re definitely ready to embark on another planning process to take us further.” Public Fears May Fuel Regulation In 2004, the “leakage” of genetically modified (GM) papaya from test fields aroused public concern among Thais about the potential social and environmental impacts of biotechnology. During field trials in a state-owned research center in Khon Kaen province, the GM papayas managed to migrate more than 1,000 kilometers to take root in many provinces across the nation. When GM papayas started showing up in public markets unbeknownst to buyers and sellers, the public questioned the state’s capability to oversee biotech research. It didn’t help that the Department of Agriculture denied any responsibility and attempted to use the judicial system to silence those who exposed the leak. “The potential damages could be huge if we introduce GM crops with improper preparedness,” warns Saree Ongsomwang, secretary general of the Foundation for Consumers. “Not only [does it have] potential health impacts on consumers, [but] GM material contamination may also threaten the country’s food security and biodiversity resources.” Public outcry has led to the drafting of biosafety legislation now under consideration by the Council of State. If the legislation is passed, a new system of controls and oversight would apply to research, testing, deployment, and exporting of GM seeds and crops. In the health care arena, stem cell research has also been the subject of public debate, with concerns being raised about safety as well as marketing claims. “Although stem cell technology opens the door for treatment of some health problems, it’s not a magic wand. Absent any protection, the public could be exposed to exaggerated marketing,” says Yot Teerawattananon of Thailand’s Health Intervention and Technology Assessment Program, citing private hospitals’ marketing of costly cord blood banking for future stem cell treatments. The Medical Council of Thailand recently released recommendations that stem cell use in Thailand be limited to research purposes. Saree would like to see a more comprehensive approach similar to the health technology assessment bodies in Europe. “What Thailand needs is an independent body to oversee, screen, and control the research and application of biotechnology,” she asserts. —Kamol Sukin

Mapping the Terrain

Mapping the Terrain

Thailand’s first National Biotechnology Policy Framework served as a roadmap for significant progress, but it had a rocky start. A look back at the Framework provides signposts to guide the way forward.

Become a Member of

Meet the Author

Thana Poopat

Nantiya Tangwisutijit

Published In

December 2010

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies